Search Results - pancreatic+cancer

19 Results

Sort By:

Identification of RNF43 Mutations in Pancreatic Cysts

Unmet Need· One third of diagnoses for surgical resection of pancreatic cysts are incorrect, leading to unnecessary surgery, medical risk, and high costs (Hammel, 2002). The current standard of care for determining pancreatic cyst type is based solely on symptom progression and imaging criteria, and histopathological analysis is only available...

Published: 6/27/2024 | Inventor(s): Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Jian Wu, Anirban Maitra, Ralph Hruban, Marco Dal Molin

Keywords(s): Cancers, Cloning Reagents, Discovery/Research Tools, Disease Indication, Nucleotide, Pancreatic Cancer, Research Reagent, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Research Tools > Nucleic Acids, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers

Large-scale Epigenomic Reprogramming Links Anabolic Glucose Metabolism to Distant Metastasis during the Evolution of Pancreatic Cancer Progression

Unmet NeedPancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer death in the western world by 2020. Subclonal populations that emerge and drive metastatic progression of the disease are associated with high mortality rates among patients. Blocking the tumorigenic potential of metastatic sites is key to improving...

Published: 6/27/2024 | Inventor(s): Andrew Feinberg, Xin Li, Christine Iacobuzio-Donahue, Oliver McDonald

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer

EXoO-Tn Tag-n-Pin the Pan-Carcinoma Tn Antigen in Human Proteome

Unmet NeedAberrant glycosylation has been implicated as a mechanism of cancer progression. Accordingly, identifying the differences in glycan structures within clinical specimens, cancer, and normal cells provides a unique opportunity to identify new biomarkers and therapeutic targets. In particular, Tn antigen (Tn) is a simple O-linked glycan structure...

Published: 6/28/2024 | Inventor(s): Hui Zhang, Weiming Yang

Keywords(s): Analytical Method, Assay, Cancers, Clinical Diagnostics, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics (Old), In Vitro Research Tool, Pancreatic Cancer, Pancreatic ductal adenocarcinoma

Category(s): Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics > Biomarkers

Most Pancreatic Ductal Adenocarcinomas have Detectable Telomere Fusions and their Detection in Pancreatic Cyst Fluids Predicts the Grade of Dysplasia of Intraductal Papillary Mucinous Neoplasms

Unmet Need Physicians must determine whether patients with cystic tumors of the pancreas will be operated on or receive further imaging and monitoring. Biomarkers that can inform the physician of the state of progression of the tumor, as well as predict the neoplastic nature of the cyst, would be valuable for determining treatment course. Specifically,...

Published: 6/27/2024 | Inventor(s): Michael Goggins, Tatsuo Hata

Keywords(s): Assay, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Pancreatic Cancer

Semaphorin 3D and Plexin D1 as New Therapeutic Targets for Pancreatic Cancer Treatment

Unmet Need: Most patients with pancreatic ductal adenocarcinoma (PDA) present with metastatic disease at the time of diagnosis or will recur with metastases after surgical treatment. Technology Overview: Semaphorin-plexin signaling mediates the migration of neuronal axons during development and of blood vessels during angiogenesis. The expression of...

Published: 6/27/2024 | Inventor(s): Lei Zheng

Keywords(s): Biomarker, Cancer Cells, Cancers, Cell Model, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Mechanism-of-action Biomarker, Pancreatic Cancer, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

Development of magnetic bead-based multiplex immunoassays of serum biomarkers for the early detection of pancreatic cancer

Pancreatic cancer is the 4th leading cause of cancer death in the United States. The majority of patients present with unresectable disease leading a median survival of 6 months and an overall 5-year survival of < 5%. The early detection of this disease is critical because surgery at an early stage is the most promising therapy that could greatly...

Published: 6/27/2024 | Inventor(s): Jin Song, Zhen Zhang, Daniel Chan

Keywords(s): Adenocarcinoma, Assay, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Sample Prep Method

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

Activators of Myosin II for Modulating Cell Mechanics

C12770: Novel Panel of Myosin II Activators for Disease Therapy and Tissue EngineeringNovelty:A panel of myosin II activators developed to treat disease and useful for tissue engineering in regenerative medicine.Value Proposition:Changes in cellular mechanics due to impaired activity of myosin II, a motor protein essential for cell division, motility,...

Published: 6/27/2024 | Inventor(s): Douglas Robinson, Alexandra Surcel, Win Pin Ng, Caren Freel Meyers

Keywords(s): Agonists/Promoters, Cancers, Disease Indication, Non-novel, Pancreatic Cancer, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Medical Devices > Regenerative Medicine, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for Cancer Therapy

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for cancer therapyJHU REF: C13142 Invention novelty: An improved glutaminase (GLS) inhibitors delivery system to enhance efficacy and prolong glutaminase inhibitor drug levels in tumor for improve treatment of pancreatic cancer. Value Proposition: Currently available glutaminase inhibitors...

Published: 6/27/2024 | Inventor(s): Barbara Slusher, Jie Fu, Justin Hanes, Qingguo Xu, Quy Hoa Le Thi, Takashi Tsukamoto

Keywords(s): Adenocarcinoma, Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Non-novel, Off-the-shelf, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Prognostic Markers in Pancreatic Cancer

TITLE: GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTSCASE NUMBER: C13433UNMET NEEDSeveral genetic alterations have been identified in pancreatic cancers, including those in certain tumor suppressor genes and in oncogene. Although the discoveries of these genes and their pathways have provided important insights into...

Published: 6/27/2024 | Inventor(s): Victor Velculescu, Mark Sausen, Vilmos Adleff, Jillian Phallen

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer, Prognostic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > Prognostics Biomarkers, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

PD-1/PD-L1 Blockade together with Vaccine Therapy Facilitates Effector T Cell Infiltration into Pancreatic Tumors

Novel Combination Therapy for Pancreatic Cancer TreatmentJHU REF: C12915Invention Novelty: The technology is the novel combination of PD1/PD-L1 blockade antibody and vaccine-based immunotherapy to treat pancreatic cancer.Value Proposition:Pancreatic cancer is one of the top cancer killers in the United States due to late detection and resistance to...

Published: 6/27/2024 | Inventor(s): Elizabeth Jaffee, Lei Zheng

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Pancreatic Cancer, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

1 2